http://clinicaltrials.gov/ct2/show/s...ow_desc=Y#desc
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
This study is currently recruiting participants.
Verified by M.D. Anderson Cancer Center, May 2009
First Received: January 29, 2007 Last Updated: May 27, 2009
History of Changes
Sponsored by:
M.D. Anderson Cancer Center
Information provided by: M.D. Anderson Cancer Center ClinicalTrials.gov Identifier: NCT00429182
Purpose Primary Objectives:
- To determine whether high-dose chemotherapy (HDCT) with purged autologous stem cell products will reduce the presence of circulating tumor cells (CTCs) among metastatic breast cancer (MBC) patients after receiving high-dose chemotherapy autologous hematopoietic stem cell transplantation.
- To determine whether reduction of CTCs will correlate with prolonged progression-free survival (PFS).
Secondary Objectives:
- To determine whether reduction of CTCs will correlate with prolonged overall survival (OS).
- To characterize the biology of CTC.
Condition Intervention Phase Breast Cancer
Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Thiotepa
Procedure: Stem Cell Transplant
Phase II
Study Type: Interventional Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study Official Title: Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients